Application of high-flux hemodialysis combined with hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of renal anemia in patients with urem
This study aimed to explore the efficacy of combining high‑flux hemodialysis (HFHD) with a hypoxia‑inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of renal anemia among patients with end-stage kidney disease. Sixty-four newly treated maintenance hemodial
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.